A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma

A novel, once-daily (o.d.), fixed-dose combination (FDC) of indacaterol acetate (IND), glycopyrronium bromide (GLY), and mometasone furoate (MF), delivered by the inhaler Breezhaler(®) device, is the first long-acting beta2-adrenergic agonist/long-acting muscarinic antagonist/inhaled corticosteroid...

Descripción completa

Detalles Bibliográficos
Autores principales: Brittain, Dominic, D’Andrea, Peter, Gruen, Emilie, Hosoe, Motoi, Jain, Devendra, Jauernig, Juergen, Pethe, Abhijit, Scosyrev, Emil, Tanase, Ana-Maria, Tillmann, Hanns-Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122880/
https://www.ncbi.nlm.nih.gov/pubmed/35072888
http://dx.doi.org/10.1007/s12325-021-02025-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122880/
https://www.ncbi.nlm.nih.gov/pubmed/35072888
http://dx.doi.org/10.1007/s12325-021-02025-w

Ejemplares similares